Get the Stockscreener App
48.41
4.67%
2.165
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $48.41, with a volume of 11.58M.
It is up +4.67% in the last 24 hours and up +10.45% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$46.25
Open:
$48.19
24h Volume:
11.58M
Relative Volume:
0.77
Market Cap:
$98.53B
Revenue:
$48.03B
Net Income/Loss:
$6.05B
P/E Ratio:
16.35
EPS:
2.9615
Net Cash Flow:
$15.30B
1W Performance:
+3.42%
1M Performance:
+10.45%
6M Performance:
+3.33%
1Y Performance:
-17.77%
1-Day Range:
$47.60
$48.62
1-Week Range:
$45.27
$48.62
52-Week Range:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
48.40 | 94.15B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,061.92 | 948.45B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
204.75 | 491.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.59 | 417.60B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.85 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
101.73 | 242.64B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers (BMY) Sees Stock Surge on Positive Drug Trial News - GuruFocus
Prudential Financial Inc. Purchases 2,334,421 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Cantor Fitzgerald reiterates neutral rating on Bristol-Myers stock - Investing.com India
Cantor Fitzgerald maintains Bristol-Myers Squibb stock rating, cites milvexian potential - Investing.com India
Novo Nordisk, Bristol-Myers and Uber rose premarket; Performance Food falls - Investing.com
Heron Bay Capital Management Has $977,000 Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Mufg Securities Americas Inc. Purchases 9,182 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
14,187 Shares in Bristol Myers Squibb Company $BMY Acquired by Neo Ivy Capital Management - MarketBeat
Brandywine Global Investment Management LLC Sells 633,786 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Legal & General Group Plc Sells 707,829 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Crashes Again: Another Trial Failure Shocks Investors - Smartkarma
Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug - Benzinga
Texas Attorney General Ken Paxton Sues Sanofi, Bristol-Myers Squibb - Hoodline
Quilter Plc Lowers Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Has $106.03 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb stock holds steady as BMO reiterates $47 target By Investing.com - Investing.com South Africa
Bristol-Myers Squibb: Navigating Challenges in a Critical Transition Phase - Ad-hoc-news.de
Texas Sues Bristol-Myers For Alleged Drug Misrepresentations - Law360
Merck, Bristol Myers Squibb plan NJ layoffs (updated) - NJBIZ
State of Texas Sues Bristol-Myers Squibb and Sanofi for Deceptive Marketing of Blood Thinner Plavix - cnhinews.com
Texas sues Bristol Myers, Sanofi for concealing blood thinner Plavix's alleged ineffectiveness - Reuters
Bristol-Myers, Sanofi Draw Texas Fraud Claims Over Plavix Safety - Bloomberg Law News
Bristol-Myers Squibb (BMY) Faces Legal Action Over Plavix Effectiveness Claims - GuruFocus
Bristol Myers, Sanofi sued by Texas over Plavix - Yahoo
What's Driving the Market Sentiment Around Bristol-Myers Squibb Co? - Benzinga
Buy Bristol Myers Squibb Stock. The Drugmaker Is Too Cheap to Ignore. - Barron's
Bristol-Myers Squibb stock holds steady as BMO reiterates $47 target - Investing.com India
Traub Capital Management LLC Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
2 Major Pharmaceutical Companies Laying Off Hundreds More In NJ - Patch
Vanguard Group Inc. Has $9.02 Billion Stake in Bristol Myers Squibb Company $BMY - MarketBeat
WBI Investments LLC Acquires New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company (BMY) Slipped due to Lowered EPS Guidance - Yahoo Finance UK
Primecap Management Co. CA Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Is Bristol Myers Squibb Company (BRM) stock a contrarian opportunityM&A Rumor & High Win Rate Trade Tips - newser.com
Pharma giant gave Irish employee three months to come up with €20,800 to cover alleged ‘overpayment’, WRC hears - The Irish Times
Bristol Myers Squibb Co. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Will Bristol Myers Squibb Company (BRM) stock beat growth indexesMarket Activity Summary & Fast Gain Swing Alerts - newser.com
Published on: 2025-11-19 14:34:44 - newser.com
Metabolic Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 576 Deals by Company A-Z, Therapy Focus and Technology Type - GlobeNewswire Inc.
Is Bristol Myers Squibb Company Celegne Contingent stock resilient in recession scenariosWeekly Gains Summary & Safe Entry Point Identification - newser.com
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Yahoo Finance UK
Is Bristol Myers Squibb Company stock oversold or undervaluedJuly 2025 Patterns & Free Fast Entry Momentum Trade Alerts - newser.com
Nordwand Advisors LLC Acquires New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Nomura Asset Management Co. Ltd. Boosts Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Empowered Funds LLC Lowers Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Biokin/BMS’s Iza-bren Hits First Phase III OS Endpoint, Albeit In China - Citeline News & Insights
Will Bristol Myers Squibb Company Celegne Contingent stock benefit from mergersWeekly Investment Report & Free Risk Controlled Daily Trade Plans - newser.com
Bristol-Myers Squibb (BMY) Announces Early Results and Amendments to Cash Tender Offers - GuruFocus
How Bristol Myers Squibb Company stock reacts to new regulationsRate Cut & Verified Momentum Watchlists - newser.com
Bristol-Myers Squibb Can Appeal Pension Suit To 2nd Circ. - Law360
Merck & Co., BMS to lay off over 300 staffers in New Jersey - FirstWord Pharma
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
1.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):